HER2 positive breast cancer patients having HER2 loss after neoadjuvant chemotherapy should still be treated with adjuvant anti-HER2 treatment

被引：0
|
作者：
Altundag, Kadri [1 ]
机构：
[1] MKA Breast Canc Clin, TR-06800 Ankara, Turkey
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2019年 / 175卷 / 01期
关键词：
D O I：
10.1007/s10549-019-05151-w
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：261 / 261
页数：1
相关论文
共 50 条
  • [31] Hormone receptor status might be a determinant for HER2 loss after HER2-targeted treatment in HER2 positive breast cancer patients
    Altundag, Kadri
    JOURNAL OF BUON, 2019, 24 (05): : 2206 - 2206
  • [32] HER2 Amplification Level and Focal/Broad Region Size as Predictors of Treatment Response in Neoadjuvant Chemotherapy and Anti-HER2 Therapy for HER2-Positive Breast Cancer
    Liao, Ning
    Zhang, Guochun
    Lv, Xinze
    Li, Kai
    Hou, Ting
    Zhang, Zhou
    CANCER RESEARCH, 2024, 84 (09)
  • [33] Anti-HER2 Th1 Response is Superior to Breast MRI in Assessing Response to Neoadjuvant Chemotherapy in Patients with HER2 Positive Breast Cancer
    De La Cruz, L. M.
    McDonald, E.
    Mick, R.
    Datta, J.
    Geha, R.
    Xu, S.
    Czerniecki, B. J.
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 : S14 - S15
  • [34] Deciphering trastuzumab resistance in residual tumor according to HER2 status after neoadjuvant trastuzumab containing regimen in HER2 positive breast cancer patients might help to choose further adjuvant anti-HER2 treatment
    Abduyev, Zohrab
    Altundag, Kadri
    JOURNAL OF BUON, 2019, 24 (05): : 2208 - 2208
  • [35] Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer
    Zheng-Jun Yang
    Fei Xin
    Zu-Jin Chen
    Yue Yu
    Xin Wang
    Xu-Chen Cao
    BMC Cancer, 24
  • [36] Quantitative digital imaging analysis of HER2 immunohistochemistry predicts the response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma
    Aidan C. Li
    Jing Zhao
    Chao Zhao
    Zhongliang Ma
    Ramon Hartage
    Yunxiang Zhang
    Xiaoxian Li
    Anil V. Parwani
    Breast Cancer Research and Treatment, 2020, 180 : 321 - 329
  • [37] Methodology Used to Determine HER2 Status Correlates with Response to Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer
    Cheng, Esther
    McIntire, Patrick
    D'Alfonso, Timothy
    Ginter, Paula
    MODERN PATHOLOGY, 2018, 31 : 54 - 54
  • [38] Prognostic significance of HER2 loss after HER2-targeted neoadjuvant treatment in patients with HER2-positive locally advanced breast cancer
    Kutlu, Yasin
    Cekin, Ruhper
    Aydin, Sabin Goktas
    Shbair, Abdallah T. M.
    Bilici, Ahmet
    Arici, Serdar
    Oven, Bala Basak
    Acikgoz, Ozgur
    Ozcan, Erkan
    Olmez, Omer Fatih
    Cakir, Asli
    Seker, Mesut
    CURRENT PROBLEMS IN CANCER, 2024, 50
  • [39] Dual HER2 blockade in adjuvant and neoadjuvant treatment of HER2-positive breast cancer: the role of pertuzumab
    Duchnowska, Renata
    ONCOLOGY IN CLINICAL PRACTICE, 2018, 14 (01): : 43 - 47
  • [40] A comparative analysis of clinical and pathologic characteristics of patients with HER2 positive breast cancer treated with neoadjuvant versus adjuvant anti-HER2 therapy: Analysis of 397 cases
    Sarode, Venetia
    Rood, Tricia
    Liu, Yulun
    Fang, Yisheng
    Sahoo, Sunati
    Peng, Yan
    Hwang, Helena
    Leitch, Marilyn
    Haley, Barbara
    CANCER RESEARCH, 2022, 82 (04)
12345